Monitoring issues pertaining to reimbursement for prescription drugs; and Food and Drug Administration legislative and regulatory issues.
Monitoring Medicare Part D issues.
Duration: November 1, 2007
to
November 30, 2018
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Pharmacy
Spending: about $2,060,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, U.S. Senate,, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
TCH Group, LLC terminated an engagement in which they represented PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA on Jan. 9, 2019.
Original Filing: 301003073.xml
Lobbying Issues
Monitoring issues pertaining to reimbursement for prescription drugs; and Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitoring Medicare Part D issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 12, 2018.
Original Filing: 300984804.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; and Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 18, 2018.
Original Filing: 300967214.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; and Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 19, 2018.
Original Filing: 300951017.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; and Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 18, 2018.
Original Filing: 300926983.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910194.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 14, 2017.
Original Filing: 300884981.xml
Lobbying Issues
General health care coverage and reimbursement for prescription drugs; implementation of and reforms to H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues, including the Prescription Drug User Fee Act Re-authorization..
H.R. 1628, American Health Care Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 18, 2017.
Original Filing: 300868110.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S.Con.Res.3 - Senate concurrent resolution setting forth the Congressional budget for the U.S. Government for the fiscal year 2017 - Healthcare related floor amendments.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847263.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828996.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act.
21st Century Cares Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 20, 2016.
Original Filing: 300816970.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding the Patient Protection and Affordable Care Act.
21st Century Cares Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program. Issues pertaining to Importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 20, 2016.
Original Filing: 300798455.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act.
21st Century Cores Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program. Issues pertaining to Importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 19, 2016.
Original Filing: 300774876.xml
Lobbying Issues
S.Con.Res.11-An original concurrent resolution setting forth the congressional budget for the United States government for fiscal year 2016.
Possible healthcare related pay-fors.
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act.
21st Century Cores Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015. H.R. 1021 - Protecting the Integrity of Medicine Act. Issues pertaining to Importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 20, 2015.
Original Filing: 300759379.xml
Lobbying Issues
S.Con.Res.11-An original concurrent resolution setting forth the congressional budget for the United States government for fiscal year 2016.
Possible healthcare related pay-fors.
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act.
21st Century Cores Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. 340B Drug Pricing Program. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015. H.R. 1021 - Protecting the Integrity of Medicine Act. Issues pertaining to Importation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 16, 2015.
Original Filing: 300737218.xml
Lobbying Issues
S.Con.Res.11-An original concurrent resolution setting forth the congressional budget for the United States government for fiscal year 2016.
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. S.31 Medicare Prescription Drug Price Negotiation Act- Provisions related to Part D program. S.141 Protecting Seniors Access to Medicare Act of 2015. H.R. 1470 SGR Repeal and Medicare Provider Payment Modernization Act of 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 20, 2015.
Original Filing: 300724191.xml
Lobbying Issues
S.Con.Res.11-An original concurrent resolution setting forth the congressional budget for the United States government for fiscal year 2016.
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare Part D issues. S.31 Medicare Prescription Drug Price Negotiation Act- Provisions related to Part D program. S.141 Protecting Seniors Access to Medicare Act of 2015. H.R. 1470 SGR Repeal and Medicare Provider Payment Modernization Act of 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696480.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. 340 B policy issues. Importation policy issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues. H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
Medicare Drug Savings Act: Part D Issues S. 117 Medicare Prescription Drug Price Negotiation Act of 2013. S. 351 Protecting Seniors Access to Medicare Act of 2013 S. 408 Medicare Prescription Drug Saving and Choice Act of 2013. 340B Drug Program Issues related to changes to the Medicare Part B reimbursement of perscription drugs; issues related to coverage and reimbursementfor those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2014
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680096.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. 340 B policy issues. Importation policy issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues. H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
Medicare Drug Savings Act: Part D Issues S. 117 Medicare Prescription Drug Price Negotiation Act of 2013. S. 351 Protecting Seniors Access to Medicare Act of 2013 S. 408 Medicare Prescription Drug Saving and Choice Act of 2013. 340B Drug Program Issues related to changes to the Medicare Part B reimbursement of perscription drugs; issues related to coverage and reimbursementfor those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2014
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 17, 2014.
Original Filing: 300660140.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. 340 B policy issues. Importation policy issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues. H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
Medicare Drug Savings Act: Part D Issues S. 117 Medicare Prescription Drug Price Negotiation Act of 2013. S. 351 Protecting Seniors Access to Medicare Act of 2013 S. 408 Medicare Prescription Drug Saving and Choice Act of 2013. 340B Drug Program Issues related to changes to the Medicare Part B reimbursement of perscription drugs; issues related to coverage and reimbursementfor those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 18, 2014.
Original Filing: 300641396.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues.
H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
Medicare Drug Savings Act: Part D Issues
S. 117 Medicare Prescription Drug Price Negotiation Act of 2013S. 351 Protecting Seniors Access to Medicare Act of 2013
S. 408 Medicare Prescription Drug Savings and Choice Act of 2013
340B Drug Program
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616104.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. S.959, "Pharmaceutical Compounding Quality and Accountability Act."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues.
H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
H.R. 2190 Medicare Drug Savings Act: Part D Issues
S. 117 Medicare Prescription Drug Price Negotiation Act of 2013S. 351 Protecting Seniors Access to Medicare Act of 2013
S. 408 Medicare Prescription Drug Savings and Choice Act of 2013
340B Drug Program
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.CON.RES.8, An original resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.
3rd Quarter, 2013
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Oct. 17, 2013.
Original Filing: 300597171.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. S.959, "Pharmaceutical Compounding Quality and Accountability Act."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues.
H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
H.R. 2190 Medicare Drug Savings Act: Part D Issues
S. 117 Medicare Prescription Drug Price Negotiation Act of 2013S. 351 Protecting Seniors Access to Medicare Act of 2013
S. 408 Medicare Prescription Drug Savings and Choice Act of 2013
340B Drug Program
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.CON.RES.8, An original resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.
2nd Quarter, 2013
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on July 17, 2013.
Original Filing: 300574676.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. Issues related to Pharmaceutical Importation. Issues related to generic drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare Part D issues.
H.R. 928 Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to patent issues.
H.R. 2190 Medicare Drug Savings Act: Part D Issues
S. 117 Medicare Prescription Drug Price Negotiation Act of 2013S. 351 Protecting Seniors Access to Medicare Act of 2013
S. 408 Medicare Prescription Drug Savings and Choice Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.CON.RES.8, An original resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.
1st Quarter, 2013
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on April 19, 2013.
Original Filing: 300555970.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. Issues related to Pharmaceutical Importation. Issues related to generic drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.CON.RES.8, An original resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.
4th Quarter, 2012
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $40,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532758.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage. S. 810 Great Ape Protection and Cost Savings Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2693, Budget Control Act of 2011: Sequestration Implementation.
3rd Quarter, 2012
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511367.xml
Lobbying Issues
General heath care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative regulatory issues. Drug Safety Issues. Drug shortage.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on July 16, 2012.
Original Filing: 300484952.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Importation. Drug Safety Issues. Drug shortage.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on April 18, 2012.
Original Filing: 300463382.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Importation. Drug Safety Issues. Drug shortage.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300443112.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Importation. Drug Safety Issues. Drug shortage.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on Oct. 18, 2011.
Original Filing: 300418163.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Importation. Drug Safety Issues. Drug shortage.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 23, HR 1249, PL112-29, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300402667.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Drug Safety Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 23 America Invents Act. H.R. 1249 The American Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $50,000. The report was filed on April 15, 2011.
Original Filing: 300365607.xml
Lobbying Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; and the Food and Drugs Administration legislative regulatory issues. Prescription Drug User Fee Act (PDUFA) Reauthorization. Drug Safety Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 23 America Invents Act. H.R. 1249 The American Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Jan. 18, 2011.
Original Filing: 300340720.xml
Lobbying Issues
H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates. H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues. H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation. H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness. H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness. H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring. H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances. S. 1203, Grow Research Opportunities with Taxcredits' Help Act: R&D tax credit provisions. S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness. S. 1679, Affordable Health Choices Act: 340B program issues, importation, and other health reform implementation issues. S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances General FDA advocacy.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally. H.R. 4872, Healthcare & Education Reconciliation Act 2010. H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: Non-interference provisions. H.R. 4213, American Jobs & Closing Tax Loopholes Act of 2010: (AMP) issues. H.R. 4899, Supplemental Appropriations Act, 2010: AMP issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws. H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements. H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding. S. 369, Preserve Access to Affordable Generics Act: patent settlements. S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions. S. 515, Patent Reform Act of 2009: reforms of the patent laws. S. 610, Patent Reform Act of 2009: reforms of the patent laws.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2010
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Oct. 20, 2010.
Original Filing: 300324044.xml
Lobbying Issues
H.R. 1548, The Pathway for Biosimilars Act; H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; S. 301, The Physician Payments Sunshine Act of 2009. Health care reform: H.R. 3200, America's Affordable Health Choices Act; S. 1796, America's Healthy Future Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; H.R. 4872, Healthcare & Education Reconciliation Act 2010. S. 1796, America's Healthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally. H.R. 3200, America's Affordable Health Choices Act; S. 300, The Medicare Prescription Drug Savings and Choice Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Extension of the R&D TAX credit and all such provisions in H.R. 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010. S. 1203 "Growth Research Opportunities with Tax Credits 'Help Act of Growth Act".
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on July 20, 2010.
Original Filing: 300300664.xml
Lobbying Issues
H.R. 1548, The Pathway for Biosimilars Act; H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; S. 301, The Physician Payments Sunshine Act of 2009. Health care reform: H.R. 3200, America's Affordable Health Choices Act; S. 1796, America's Healthy Future Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; H.R. 4872, Healthcare & Education Reconciliation Act 2010. S. 1796, America's Healthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally. H.R. 3200, America's Affordable Health Choices Act; S. 300, The Medicare Prescription Drug Savings and Choice Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Extension of the R&D TAX credit and all such provisions in H.R. 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010. S. 1203 "Growth Research Opportunities with Tax Credits 'Help Act of Growth Act".
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on April 20, 2010.
Original Filing: 300272334.xml
Lobbying Issues
H.R. 1548, The Pathway for Biosimilars Act; H.R. 1427, Promoting Innovations and Lifesaving Medicines Act; S. 301, The Physician Payments Sunshine Act of 2009. Health care reform: H.R. 3200, America's Affordable Health Choices Act; S. 1796, America's Healthy Future Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, The Health Care and Education Reconciliation Act of 2010. S. 525, S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Issues pertaining to: prescription drug importation, comparative effectiveness, follow-on biologics, Medicare prescription drug coverage, Medicaid rebates.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; H.R. 4872, Healthcare & Education Reconciliation Act 2010. S. 1796, America's Healthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally. H.R. 3200, America's Affordable Health Choices Act; S. 300, The Medicare Prescription Drug Savings and Choice Act of 2009.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Jan. 20, 2010.
Original Filing: 300245998.xml
Lobbying Issues
H.R. 444, 340B Program Improvement Integrity Act; 340B program issues; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness; H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, regulatory approval for follow-on biologics, drug labeling, access to clinical trials, importation [S.A. 2793], health reform issues generally; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, 340B program issues, comparative effectiveness, importation, health reform issues generally; S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements; S. 488, Access to Cancer Clinical Trials Act of 2009: access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory approval pathway for follow-on biologics, 340B program issues, importation; S. 1796, America's Health Future Act of 2009: comparative effectiveness, importation, health reform issues generally
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; S. 1796, America'sHealthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 573, To amend the Federal Food , Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; H.R. 3590, Patient Protection and Affordable Care Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, patent settlements, and authorized generics; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, and patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 501, To amend the Federal Food, Drug, and Cosmetics Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; S. 515, Patent Reform Act of 2009: reforms of the patent laws; S. 610, Patent Reform Act of 2009: reforms of the patent laws: S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; International intellectual property issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 2982, Department of Homeland Security Appropriations Act, 2010: importation; H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; S. 1298, Department of Homeland Security Appropriations Act, 2010: importation; S. 1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; H.R. 3288, Consolidated Appropriations Act:comparative effectiveness, NIH funding, pandemic funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216582.xml
Lobbying Issues
S.- America's Healthy Future Act. (Finance Committee Version); S. 1679- The Affordable Health Choices Act; H.R. 3200: America's Affordable Health Choices Act of 2009; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes and Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory pathway for follow-on biologics, 340B program issues; H.R. 759, Food and Drug Administration Globalization Act, 2009: import safety; S. 623, Access to Life-Saving Medicine Act; Follow-on biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 301, Physician Payments Sunshine Act of 2009: transparency issues; S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues; S. 458, False Claims Act Clarification Act of 2009: liability issues; S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues; Health care reform issues, Senate Finance Committee options papers; H.R. 1788, False Claims Act of 2009; H.R. 684, Medicare Prescription Drug Cost Equalization Act, Part D issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1260, Patent Reform Act of 2009: patent reform issues; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 515, Patent Reform Act of 2009: patent reform issues; S. 610, Patent Reform Act of 2009: patent reform issues; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 1298, F.Y. 2010 Homeland Security Appropriations, drug importation issues. Monitored appropriation process; S. 1406, F.Y. 2010 Agriculture Appropriations, FDA funding, importation, Monitored appropriation process; H.R. 2847, F.Y. 2010 Commerce, Justice, Science Appropriations, importation issues. Monitored appropriations process.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on July 20, 2009.
Original Filing: 300191945.xml
Lobbying Issues
Affordable Health Choice Act. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 6331 Medicare Improvements for Patients and Providers Act of 2008, implementation of the Medicare Part D Program; S 3101 Medicare Improvements or Patients and Providers Act of 2008; Part D, Electronic Prescribing, Medicaid Pharmacy Reimbursement. S 3118, Preserving Access to Medicare Act of 2008.HR 4, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; HR 758, Price Disclosure Regarding Treatment of Breast Cancer; S 3330 The Medicare Prescription Drug Savings and Choice Act 2009:HR 5605, Physician Payments Sunshine Act of 2008: transparency issues; HR 6884, Medicare Prescription Drug Cost Equalization Act: Part D issues; S 3, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; S 2029, Physician Payments Sunshine Act of 2007: transparency issues; S 2041, False Claims Act Correction Act of 2007: liability issues; S 3118, Preserving Access to Medicare Act of 2008: electronic prescribing, Part D data disclosure, and other issues; S 3396, The Independent Drug Education and Outreach Act of 2008: direct to physician marketing; S 3408, Comparative Effectiveness Research Act of 2008: comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S 316, Preserve Access to Affordable Generics Act, patent settlements International Property issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 298, Homeland Security Appropriations, Drug Importation issues. Monitored appropriations process. FY2010 Senate Budget Resolution (S. Con Res. 13) Healthcare proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, TCH Group, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300163213.xml
Lobbying Issues
HR 2 Children's Health Insurance Program Reauthorization Act 2009. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1 The American Recovery & Reinvestment Act of 2009: Comparative Effectiveness; HR 6331 Medicare Improvements for Patients and Providers Act of 2008, implementation of the Medicare Part D Program; HR 3162 Children's Health and Medicare Protection Act of 2007; S 3101 Medicare Improvements or Patients and Providers Act of 2008; Part D, Electronic Prescribing, Medicaid Pharmacy Reimbursement. S 3118, Preserving Access to Medicare Act of 2008.HR 4, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; HR 758, Price Disclosure Regarding Treatment of Breast Cancer; S 3330 The Medicare Prescription Drug Savings and Choice Act 2009:HR 5605, Physician Payments Sunshine Act of 2008: transparency issues; HR 6884, Medicare Prescription Drug Cost Equalization Act: Part D issues; S 3, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; S 2029, Physician Payments Sunshine Act of 2007: transparency issues; S 2041, False Claims Act Correction Act of 2007: liability issues; S 3118, Preserving Access to Medicare Act of 2008: electronic prescribing, Part D data disclosure, and other issues; S 3396, The Independent Drug Education and Outreach ACt of 2008: direct to physician marketing; S 3408, Comparative Effectiveness Research Act of 2008: comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S 316, Preserve Access to Affordable Generics Act, patent settlements International Property issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 3230, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2009: HHS budget, importation, comparative effectiveness, and Part D benefit issues. S. 3289, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2009; FDA budget and importation issues. Monitored appropriations process. FY2010 Senate Budget Resolution (S. Con Res. 13) Healthcare proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, TCH Group (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Jan. 21, 2009.
Original Filing: 300131723.xml
Lobbying Issues
HR 380, S 623, Access to Life-Saving Medicine Act; Follow-on biologics, importation; HR 3610 Food and Drug Import Safety Act of 2007; Import safety; HR 5839, Safeguard Americans Pharmaceuticals Act; S 2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR 1038, Access to Life-Saving Medicine Act; follow-on biologics; H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR 3610, Food and Drug Import Safety Act of 2007: import safetyHR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 6331 Medicare Improvements for Patients and Providers Act of 2008, implementation of the Medicare Part D Program; HR 3162 Children's Health and Medicare Protection Act of 2007; S 3101 Medicare Improvements or Patients and Providers Act of 2008; Part D, Electronic Prescribing, Medicaid Pharmacy Reimbursement. S 3118, Preserving Access to Medicare Act of 2008. HR 4, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; HR 758, Price Disclosure Regarding Treatment of Breast Cancer: transparency; HR 5605, Physician Payments Sunshine Act of 2008: transparency issues; HR 6884, Medicare Prescription Drug Cost Equalization Act: Part D issues; S 3, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues; S 2029, Physician Payments Sunshine Act of 2007: transparency issues; S 2041, False Claims Act Correction Act of 2007: liability issues; S 3118, Preserving Access to Medicare Act of 2008: electronic prescribing, Part D data disclosure, and other issues; S 3396, The Independent Drug Education and Outreach ACt of 2008: direct to physician marketing; S 3408, Comparative Effectiveness Research Act of 2008: comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S 316, Preserve Access to Affordable Generics Act, patent settlements International Property issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 3230, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2009: HHS budget, importation, comparative effectiveness, and Part D benefit issues. S. 3289, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2009; FDA budget and importation issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, TCH Group (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on Oct. 20, 2008.
Original Filing: 300107620.xml
Lobbying Issues
HR 380, S 623, Access to Life-Saving Medicine Act; Follow-on biologics; HR 3610 Food and Drug Import Safety Act of 2007; Import safety; HR 5839, Safeguard Americans Pharmaceuticals Act; S 2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 6331 Medicare Improvements for Patients and Providers Act of 2008, implementation of the Medicare Part D Program;
HR 3162 Children's Health and Medicare Protection Act of 2007; S 3101 Medicare Improvements or Patients and Providers Act of 2008; Part D, Electronic Prescribing, Medicaid Pharmacy Reimbursement. S. 3118, Preserving Access to Medicare Act of 2008.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S 316, Preserve Access to Affordable Generics Act, patent settlements International Property Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2008
In Q2, TCH Group, LLC (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on July 21, 2008.
Original Filing: 300077886.xml
Lobbying Issues
S. 1082, Food and Drug Administration Revitalization Act of 2007 (Importation, Follow-On Biologics, Patent settlements, Drug afety or PDUFA). HR 2900, Food and Drug Administration Amendments Act of 2007 (Drug Safety & PDUFA).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 4 Medicare Prescription Drug Price Negotiation Act of 2007, Part D Benefit. S. 3 Medicare Prescription Drug Price Negotiation Act of 2007, Part D Benefit. S. 3101, HR 6331 Medicare Improvements for Patients and Providers Act of 2008.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S. 316, Preserve Access to Affordable Generics Act, patent settlements International Intellectual Property Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
In Q1, Tongour Simpson Holsclaw and Cooney, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $60,000. The report was filed on April 21, 2008.
Original Filing: 300049741.xml
Lobbying Issues
S. 1082, Food and Drug Administration Revitalization Act of 2007 (Importation, Follow-On Biologics, Patent settlements, Drug Safety or PDUFA). HR 2900, Food and Drug Administration Amendments Act of 2007 (Drug Safety & PDUFA).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 4 Medicare Prescription Drug Price Negotiation Act of 2007, Part D Benefit. S. 3 Medicare Prescription Drug Price Negotiation Act of 2007, Part D Benefit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, patent issues HR 1908, Patent Reform Act of 2007, patent issues S. 316, Preserve Access to Affordable Generics Act, patent settlements International Intellectual Property Issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
0th Quarter, 2007
In MM, Tongour Simpson Holsclaw and Cooney, LLC lobbied for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA , earning $120,000. The report was filed on Aug. 3, 2007.
Original Filing: 200045302.xml
Lobbying Issues
S. 109- Pharmaceutical Market Access Act of 2005: S. 184- Safe Import Act of 2005; H.R. 700, S. 334-Pharmaceutical Market Access and Drug Safety Act of 2005; and S. 930 Food and Drug Administration Safety Act of 2005. S. 1082- Prescription Drug User Fee Act & Drug Safety. H.R. 1038, S. 623- Bill to amend the Public Health Service Act to provide for the licensing of comparable and interchangeable biological products.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate